New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLivagen vs PT-141 (Bremelanotide)

Livagen vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Livagen
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
Short (minutes); gene-regulatory effects are sustained
2–3 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.5–1.75 mg
Frequency
Daily for 10–30 days
As needed (not daily)
Key Benefits
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With